FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297434> ?p ?o ?g. }

• W4286297434 endingPage "3579" @default.
• W4286297434 startingPage "3579" @default.
• W4286297434 abstract "3579 Background: A proprietary in vivo target discovery screen identified creatine kinase-B (CKB) as a cancer driver in KRAS mutant (KRAS-mut) CRC. CKB promotes tumor growth and survival under hypoxia. CKB generates the energetic metabolite phospho-creatine (PCr), which is imported into cells through the creatine transporter, SLC6A8. PCr generates intracellular ATP that enables tumoral survival. RGX-202-01 is a small molecule inhibitor of SLC6A8 that depletes intracellular PCr and ATP, resulting in apoptosis. In a completed Phase 1a study, RGX-202-01 monotherapy demonstrated objective anti-tumor activity in the relapsed/refractory KRAS-mut CRC setting without dose-limiting toxicity. The objectives of this ongoing Phase 1b study are to evaluate safety, PK/PD, and efficacy of RGX-202-01 in combination with standard-of-care (SOC) FOLFIRI + BEV in second-line CRC, a setting where SOC therapy results in an ORR and mPFS of approximately 15% and 6 months, respectively. Methods: Subjects with advanced CRC who had disease progression after receiving a first line oxaliplatin-containing regimen were eligible. The dose expansion phase of the study was restricted to CKB-expressing CRC tumors. As of 01-14-2022, 16 patients (pts) have been enrolled. 8 pts were enrolled in 2 dose escalation cohorts of RGX-202-01: 2400mg BID (4 pts) and 3000mg BID (4 pts) combined with FOLFIRI and BEV. 8 pts were enrolled in the dose expansion phase of the study and received RGX-202-01 3000mg BID combined with FOLFIRI and BEV Results: No DLTs were observed and the MTD was not reached in the dose escalation phase. Grade 3 TRAEs were observed in 25% of pts. Most common TRAEs were GI in nature. There were no Grade 4-5 TRAEs. PK analysis showed sustained RGX-202-01 drug exposures in both escalation cohorts above target levels (IC 50 ). Serum and urine creatine measurements indicated robust SLC6A8 target inhibition. 9 pts had KRAS-mut CRC, and all were evaluable for RECIST 1.1 response. 4 of these pts had cPR,1 patient had uPR and 4 pts had SD as best response (ORR 56%, DCR 100%). 5 of these pts remain on therapy ranging from 11-54 weeks and a patient with a cPR at 16 weeks followed by surgery with curative intent remains with NED at 24 weeks after surgery. Seven pts had KRAS WT CRC, of which 3 were evaluable (2 pts are pending 1 st scan assessment; 2 pts are off study and did not receive 1 full cycle of treatment). Of the 3 KRAS WT evaluable pts, all had SD as best response. 2 were on study for 38 and 24 weeks respectively and 1 is ongoing at 16 weeks. Conclusions: RGX-202-01 combined with FOLFIRI and BEV was well tolerated with no DLTs at the dose levels evaluated which induced potent inhibition of SLC6A8. Antitumor activity was noted in KRAS mutated colorectal cancer, consistent with preferential pre-clinical activity in RAS mutated tumors. Enrollment in the expansion phase continues. Clinical trial information: NCT03597581." @default.
• W4286297434 created "2022-07-21" @default.
• W4286297434 creator A5011855498 @default.
• W4286297434 creator A5011905014 @default.
• W4286297434 creator A5018054038 @default.
• W4286297434 creator A5024083755 @default.
• W4286297434 creator A5026007678 @default.
• W4286297434 creator A5027630636 @default.
• W4286297434 creator A5030445043 @default.
• W4286297434 creator A5031539570 @default.
• W4286297434 creator A5034045594 @default.
• W4286297434 creator A5037497042 @default.
• W4286297434 creator A5041536802 @default.
• W4286297434 creator A5050232356 @default.
• W4286297434 creator A5053143387 @default.
• W4286297434 creator A5056491710 @default.
• W4286297434 creator A5060937197 @default.
• W4286297434 creator A5062273071 @default.
• W4286297434 creator A5064323680 @default.
• W4286297434 creator A5071147915 @default.
• W4286297434 creator A5072470914 @default.
• W4286297434 creator A5086781190 @default.
• W4286297434 date "2022-06-01" @default.
• W4286297434 modified "2023-09-25" @default.
• W4286297434 title "Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)." @default.
• W4286297434 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3579" @default.
• W4286297434 hasPublicationYear "2022" @default.
• W4286297434 type Work @default.
• W4286297434 citedByCount "1" @default.
• W4286297434 countsByYear W42862974342023 @default.
• W4286297434 crossrefType "journal-article" @default.
• W4286297434 hasAuthorship W4286297434A5011855498 @default.
• W4286297434 hasAuthorship W4286297434A5011905014 @default.
• W4286297434 hasAuthorship W4286297434A5018054038 @default.
• W4286297434 hasAuthorship W4286297434A5024083755 @default.
• W4286297434 hasAuthorship W4286297434A5026007678 @default.
• W4286297434 hasAuthorship W4286297434A5027630636 @default.
• W4286297434 hasAuthorship W4286297434A5030445043 @default.
• W4286297434 hasAuthorship W4286297434A5031539570 @default.
• W4286297434 hasAuthorship W4286297434A5034045594 @default.
• W4286297434 hasAuthorship W4286297434A5037497042 @default.
• W4286297434 hasAuthorship W4286297434A5041536802 @default.
• W4286297434 hasAuthorship W4286297434A5050232356 @default.
• W4286297434 hasAuthorship W4286297434A5053143387 @default.
• W4286297434 hasAuthorship W4286297434A5056491710 @default.
• W4286297434 hasAuthorship W4286297434A5060937197 @default.
• W4286297434 hasAuthorship W4286297434A5062273071 @default.
• W4286297434 hasAuthorship W4286297434A5064323680 @default.
• W4286297434 hasAuthorship W4286297434A5071147915 @default.
• W4286297434 hasAuthorship W4286297434A5072470914 @default.
• W4286297434 hasAuthorship W4286297434A5086781190 @default.
• W4286297434 hasConcept C121608353 @default.
• W4286297434 hasConcept C126322002 @default.
• W4286297434 hasConcept C143998085 @default.
• W4286297434 hasConcept C2776694085 @default.
• W4286297434 hasConcept C2776705615 @default.
• W4286297434 hasConcept C2777802072 @default.
• W4286297434 hasConcept C2780259306 @default.
• W4286297434 hasConcept C2780962732 @default.
• W4286297434 hasConcept C2781187634 @default.
• W4286297434 hasConcept C2781413609 @default.
• W4286297434 hasConcept C29730261 @default.
• W4286297434 hasConcept C31760486 @default.
• W4286297434 hasConcept C502942594 @default.
• W4286297434 hasConcept C526805850 @default.
• W4286297434 hasConcept C71924100 @default.
• W4286297434 hasConcept C98274493 @default.
• W4286297434 hasConceptScore W4286297434C121608353 @default.
• W4286297434 hasConceptScore W4286297434C126322002 @default.
• W4286297434 hasConceptScore W4286297434C143998085 @default.
• W4286297434 hasConceptScore W4286297434C2776694085 @default.
• W4286297434 hasConceptScore W4286297434C2776705615 @default.
• W4286297434 hasConceptScore W4286297434C2777802072 @default.
• W4286297434 hasConceptScore W4286297434C2780259306 @default.
• W4286297434 hasConceptScore W4286297434C2780962732 @default.
• W4286297434 hasConceptScore W4286297434C2781187634 @default.
• W4286297434 hasConceptScore W4286297434C2781413609 @default.
• W4286297434 hasConceptScore W4286297434C29730261 @default.
• W4286297434 hasConceptScore W4286297434C31760486 @default.
• W4286297434 hasConceptScore W4286297434C502942594 @default.
• W4286297434 hasConceptScore W4286297434C526805850 @default.
• W4286297434 hasConceptScore W4286297434C71924100 @default.
• W4286297434 hasConceptScore W4286297434C98274493 @default.
• W4286297434 hasIssue "16_suppl" @default.
• W4286297434 hasLocation W42862974341 @default.
• W4286297434 hasOpenAccess W4286297434 @default.
• W4286297434 hasPrimaryLocation W42862974341 @default.
• W4286297434 hasRelatedWork W2010928484 @default.
• W4286297434 hasRelatedWork W2014795358 @default.
• W4286297434 hasRelatedWork W2051540233 @default.
• W4286297434 hasRelatedWork W2071471252 @default.
• W4286297434 hasRelatedWork W2101986864 @default.
• W4286297434 hasRelatedWork W2591445974 @default.
• W4286297434 hasRelatedWork W2617055067 @default.
• W4286297434 hasRelatedWork W2712978371 @default.
• W4286297434 hasRelatedWork W2908369437 @default.
• W4286297434 hasRelatedWork W2939662662 @default.
• W4286297434 hasVolume "40" @default.

• next